Jacob, Suma http://orcid.org/0000-0001-7434-7398
Anagnostou, Evdokia http://orcid.org/0000-0002-3455-9887
Hollander, Eric http://orcid.org/0000-0003-4196-0596
Jou, Roger http://orcid.org/0000-0002-7501-7865
McNamara, Nora http://orcid.org/0000-0002-0107-2079
Sikich, Linmarie http://orcid.org/0000-0001-9816-1598
Tobe, Russell http://orcid.org/0000-0002-7738-8344
Murphy, Declan http://orcid.org/0000-0002-6664-7451
McCracken, James http://orcid.org/0000-0003-0370-0777
Ashford, Elizabeth http://orcid.org/0000-0003-2144-7197
Chatham, Christopher http://orcid.org/0000-0003-4427-8285
Clinch, Susanne http://orcid.org/0000-0002-3458-0117
Smith, Janice http://orcid.org/0000-0002-7267-5774
Sanders, Kevin http://orcid.org/0000-0002-6382-5072
Murtagh, Lorraine http://orcid.org/0000-0003-3315-2388
Noeldeke, Jana http://orcid.org/0000-0002-4119-6076
Veenstra-VanderWeele, Jeremy http://orcid.org/0000-0002-6349-1076
Funding for this research was provided by:
F. Hoffmann-La Roche Ltd
Article History
Received: 8 February 2022
Accepted: 31 May 2022
First Online: 11 June 2022
Declarations
:
: Not applicable.
: Not applicable.
: SJ has received grant support from NIH and F. Hoffmann-La Roche Ltd and has attended advisory boards for Fraser, Minnesota Independence College & Community, and F. Hoffmann-La Roche Ltd. EA has received grant support from F. Hoffmann-La Roche Ltd and SynapDx; royalties from APPI, Springer, and Wiley; has acted as a consultant for Quadrant, F. Hoffmann-La Roche Ltd, and SynapDx; has received honorarium for a webinar from AIDE; has a patent on anxiety meter; and has received a study drug and in kind supports from AMO Pharma. EH has received research grants from the Department of Defense, Food and Drug Administration, GW Pharma, and F. Hoffmann-La Roche Ltd; and editorial stipends from Elsevier; and served on scientific advisory boards for GW Pharma and F. Hoffmann-La Roche Ltd. RJ’s institution received payments for clinical trial agreements from Roche Translational & Clinical Research Center, Inc. and Genentech, Inc. NM has provided research support to F. Hoffmann-La Roche Ltd; and consulted for Shire; grant support has been received from Forest Research Institute, Genentech, Lundbeck, Pfizer, F. Hoffmann-La Roche Ltd, Shire, Sunovion, and Zynerba. LS has received funding from the National Institute of Child Health and Human Development; was paid by F. Hoffmann-La Roche Ltd as a clinical research site investigator for involvement in conducting the VANILLA and aV1ation studies; has attended an advisory board for F. Hoffmann-La Roche Ltd; and has a patent pending for new formulation of intranasal oxytocin by Duke University; part of her salary is paid by the Duke Clinical Research Institute where she is providing thought leadership for trials sponsored by Tris Pharmaceuticals. RT has received grant support from Janssen and F. Hoffmann-La Roche Ltd; and has attended advisory boards for F. Hoffmann-La Roche Ltd. DM receives funding support from the EU/EFPIA/SFARI/Autistica/AUTISM SPEAKS Innovative Medicines Initiative 2 Joint Undertaking (AIMS-2-TRIALS Grant No. 777394); has received grant support from F Hoffmann-La Roche and Shire; royalties from Springer and Wiley; and has attended advisory boards for F Hoffmann-La Roche and Servier. JM has received research support from F. Hoffmann-La Roche Ltd; has attended advisory boards for GW Pharmaceuticals and F. Hoffmann-La Roche Ltd; and was a consultant for Octopharma and TRIS Pharmaceuticals. JV-VW has received research support from NIH, the Simons Foundation, Health Canada, F. Hoffmann-La Roche Ltd, Janssen, Acadia, and Zynerba; royalties from Springer and Wiley; honoraria for lectures at the American Academy of Child and Adolescent Psychiatry, Karolinska Institute, Mount Sinai, National Institute of Neurological Disease and Stroke, Florida Atlantic University, UCLA, Stanford University, Child Mind Institute, and Pennsylvania State University; has attended advisory boards for Roche; serves on the medical and/or scientific advisory boards for Autism Speaks, the Simons Foundation Autism Research Initiative, and the Brain Behavior Research Foundation; and serves as the co-chair of the Autism and Intellectual Disability Committee for the American Academy of Child and Adolescent Psychiatry. EAs is an employee of F. Hoffmann-La Roche Ltd, and has stock options in F. Hoffmann-La Roche Ltd. CC and SC are employees of F. Hoffmann-La Roche Ltd, and have stocks in F. Hoffmann-La Roche Ltd. JS, JN, KS, and LM are employees of F. Hoffmann-La Roche Ltd and have stocks and stock options in F. Hoffmann-La Roche Ltd.